The good news is that ATL1102 was effective in over 70 MS...

The good news is that ATL1102 was effective in over 70 MS patients so it has good chance to show some great results in the ongoing much smaller DMD trial .
https://finfeed.com/small-caps/biotech/anp-why-partnering-big-biotech-has-its-benefits/

ANP is one of only a few companies working in the DMD space targeting the largely unmet need of treating the inflammation associated with the disease.

This is a market that is significantly underserved, meaning there is substantial value creation potential as evidenced by comparable DMD therapeutics company Sarepta Therapeutics (NASDAQ:SRPT).

ANP anticipate that its drug could be complementary to other DMD programs as treatment development is across all DMD intervention points, as seen below.

These other potentially complementary programs include Sarepta Therapeutics’ Dystrophin restoration treatment — Eteplirsen (Exondys 51)— which was approved in late 2016.

Note that prior to Exondys 51 receiving approval from the FDA, Sarepta had a market capitalisation of around just US$60 million. Once Exondys 51 was approved, Sarepta’s market cap increased to US$3.3 billion, and is now at $7.8 billion.

Exondys 51 was approved under the accelerated approval pathway based on the surrogate endpoint of dystrophin increase in skeletal muscle observed in some Exondys 51-treated patients.

Notably, William Goolsbee, the former Chairman of Sarepta, is a non-executive director of ANP and the inventor of Exondys 51, Professor Steve Wilton (Murdoch University, Perth), is a member of the ANP Scientific Advisory Board.

The company’s scientific advisory board members are internationally renowned experts with both DMD and related drug commercialisation experience in the space to guide development.

In addition to DMD therapies, the company is seeking to create, develop and commercialise novel antisense therapeutics for Multiple Sclerosis (MS), and Acromegaly. It has an advanced stage product pipeline with two compounds with positive Phase II clinical results published in high quality peer reviewed scientific journals.